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CORRESPONDENCE
Letters to the Editor
Blood Pressure Levels
on Progression of
Coronary Atherosclerosis
The provocative study by Sipahi et al. (1) looking at progressions
of coronary artery disease (CAD) in hypertension by intravascular
ultrasound (IVUS) and the accompanying editorial by Tobis and
Fonarow (2) do not quite clearly distinguish between the effects of
blood pressure (BP) lowering on prevention or progression of
CAD and the effects of BP lowering as a treatment modality in
patients with manifest CAD. There is little surprise that the lower
the BP, the better CAD will be prevented or its progression
reversed. Numerous clinical and experimental low BP models are
characterized by little, if any, atheromatosis in the exposed vascular
bed. In fact, to put it pointedly, a zero BP would probably
eliminate CAD completely. However, in patients with established
CAD, several studies have shown that lowering diastolic pressure
below certain levels will increase the risk of acute coronary events.
Based on our recent findings of a subanalysis of the 22,000-
patient INVEST (International Verapamil-Trandolapril Study)
(3), we would like to caution about too aggressive BP lowering in
hypertensive patients with CAD. This holds particularly true for
diastolic pressure and less so for systolic pressure. In the INVEST
study (3), the nadir for primary outcome (all-cause death and total
myocardial infarction) was J-shaped, with a nadir at 119/84 mm
Hg (3). When diastolic pressure dropped below 70 mm Hg the
adjusted hazard ratio of primary outcome doubled, and below 60
mm Hg it quadrupled. Because the coronary arteries are perfused
during diastole only, coronary perfusion may become hampered
when diastolic pressure falls excessively in patients at risk (i.e.,
those with CAD). Of note, in the study by Sipahi et al. (1) only
systolic but not diastolic pressure was a significant determinant of
progression of CAD. Thus, their concluding statement that “the
most favorable rate of progression of coronary atherosclerosis is
observed in patients whose BP falls within the “normal” Joint
National Commission-7 category (i.e., systolic BP 120 mm Hg
and diastolic BP80 mmHg)” and that “the optimal BP goal may
be substantially lower than the140/90 mmHg” should be amended
by refraining from identifying any levels of diastolic pressure.
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Reply
Regarding our study (1), Dr. Messerli et al. state that, in patients
with coronary disease, lowering diastolic blood pressure (BP)
below certain levels will increase risk of acute coronary events, and
they urge us to amend our conclusion, stating “the most favorable
rate of progression of coronary atherosclerosis is observed in
patients whose BP falls within the ‘normal’ Joint National
Commission-7 category (i.e., systolic BP 120 mm Hg and
diastolic BP 80 mm Hg).” They base their argument on the
secondary analysis of the INVEST (International Verapamil-
Trandolapril Study), which suggested a J-shaped relationship
between diastolic BP and the primary outcome that included not
only all-cause death and nonfatal myocardial infarction (MI), as
stated in the above letter, but also nonfatal stroke (2).
However, in the INVEST study there were profound imbal-
ances in the baseline characteristics of patients with lower and
higher diastolic BP. For example, as compared to patients with
a diastolic BP of 70 to 80 mm Hg, patients with diastolic
BP 60 mm Hg were older (74 vs. 67 years), more likely to
have a history of MI (47% vs. 32%), bypass surgery and
angioplasty (48% vs. 28%), and diabetes (44% vs. 29%). More
importantly, they were about 4 times more likely to have heart
failure (22% vs. 5%) and cancer (11% vs. 3%). Indeed, when
adjusted for these confounders, the J-shaped relationship be-
tween diastolic BP and the primary outcome disappeared. This
shows that the increased primary outcome with lower diastolic
BP levels was due to the fact that these patients were sicker
beforehand (i.e., reverse causality). In fact, analysis of MRFIT
(Multiple Risk Factor Intervention Trial) data involving more
than 300,000 men with a median follow-up of 22 years showed
that, within the normal BP category of 120/80 mm Hg, there
exists no relationship between diastolic BP and cardiovascular
disease mortality (3). Our conclusion about the importance of
having normal BP levels to slow progression or induce regres-
sion of coronary atherosclerosis as assessed by intravascular
ultrasound is also supported by other epidemiological data
including the Framingham study, which showed that incidence
of MI is lowest in patients with normal BP, intermediate in
those with prehypertension, and highest in those with hyper-
tension (4).
We thank Dr. Messerli et al. for their interest in our study.
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